000027158 000__ 04332cam\a2200673\i\4500
000027158 001__ 27158
000027158 003__ SzGeWIPO
000027158 005__ 20230616124553.0
000027158 008__ 130211s20132013enk\\\\\rb\\\\001\0\eng\d
000027158 020__ $$a9780857932457$$qPrint
000027158 020__ $$a9780857932464$$qeBook
000027158 035__ $$a(wipo)31275373X
000027158 035__ $$a(OCoLC)1161306436
000027158 040__ $$aSzGeWIPO$$beng$$erda$$cSzGeWIPO$$dCaBNVSL
000027158 041__ $$aeng
000027158 043__ $$an-us---
000027158 050_4 $$aK1519.D78$$bP53 2013
000027158 050_4 $$aHD9665.5$$b.P43 2013
000027158 08204 $$a346.0486$$223
000027158 084__ $$aG 25 DRE.P
000027158 1001_ $$aDrexl, Josef.,$$aLee, Nari.$$eEditors.
000027158 24510 $$aPharmaceutical Innovation, Competition and Patent Law :$$bA Trilateral Perspective.
000027158 264_1 $$aCheltenham, UK :$$bEdward Elgar,$$c2013.
000027158 300__ $$a352 pages ;$$c25 cm
000027158 336__ $$atext$$btxt$$2rdacontent
000027158 337__ $$aunmediated$$bn$$2rdamedia
000027158 338__ $$avolume$$bnc$$2rdacarrier
000027158 504__ $$aIncludes bibliographical references and index.
000027158 5050_ $$aIntroduction -- Part I: Patent Protection for Pharmaceutical Methods -- 1. The Patentability of Genetic Diagnostics in US Law and Policy -- 2. Patentability of Pharmaceutical Innovations: The European Perspective -- 3. Patentability of Medical Methods in Japan -- Part II: Data Exclusivity And Patent Term Extension: Convergence Or Divergence -- 4. Patent Term Restoration and Non-Patent Exclusivity in the US -- 5. Clinical Data, Data Exclusivity and Private Investment Protection in Europe -- 6. Patent Term Extension in Japan: An Academic and Comparative Perspective -- 7. Recent UK Case Law on Supplementary Protection Certificates -- 8. Patent Term Extension in Japan: Focusing on the Pacif Capsule Decision -- Part III: Balancing Incentives and Competition in Europe -- 9. Strategic Patenting by the Pharmaceutical Industry: Towards a Concept of Abusive Practices of Protection -- 10. Anticompetitive Marketing in the Context of Pharmaceutical Switching in Europe -- 11. AstraZeneca and the EU Sector Inquiry: When Do Patent Filings Violate Competition Law? -- Index
000027158 520__ $$aPublic health, safety and access to reasonably priced medicine are common policy goals of pharmaceutical regulations. As both the context for innovation and competitive structure change, industry actors dynamically challenge the balance between the incentive for protection and the achievement of those policy goals.  Considering the arguments from the perspectives of innovation, competition law and patent law, this book explores the difficult question of balancing protection with access, highlighting the difficulties in harmonization and coordination. The contributors to this book, including academics, judges and practitioners from Europe, the US and Japan, explore to what extent patent strategies and life-cycle management practices take advantage of patent laws and health-care regulation and disrupt the necessary balance between incentives for innovation and access to affordable medicine and health care.  Addressing fundamental questions in the field of pharmaceutical innovation, this book will appeal to scholars and practitioners in intellectual property, competition law and life sciences regulation, as well as pharmaceutical companies and regulators.
000027158 650_0 $$aDrugs$$xPatents$$zUnited States.
000027158 650_0 $$aAntitrust law$$zEuropean Union countries.
000027158 650_0 $$aPharmaceutical industry$$xTechnological innovations.
000027158 650_0 $$aPharmaceutical industry$$zUnited States.
000027158 650_0 $$aProduct life cycle$$zUnited States.
000027158 650_0 $$aPharmaceutical industry.
000027158 650_0 $$aProduct life cycle.
000027158 650_0 $$aAntitrust law.
000027158 650_0 $$aCompetition.
000027158 650_0 $$aPatent laws and legislation.
000027158 650_0 $$aPatents$$zEurope.
000027158 650_0 $$aIntellectual property$$zEurope.
000027158 650_4 $$aPharmaceutical innovations
000027158 650_4 $$aPatents
000027158 650_6 $$aCompétitivité (Économie)
000027158 650_6 $$aMédicaments$$vBrevets d'invention.
000027158 650_6 $$aBrevets d'invention$$xDroit.
000027158 650_6 $$aIndustrie pharmaceutique$$xInnovations.
000027158 651_0 $$aEurope$$xCommerce$$xLaw and legislation.
000027158 651_0 $$aJapan$$xCommerce$$xLaw and legislation.
000027158 651_0 $$aGermany$$xCommerce$$xLaw and legislation.
000027158 651_0 $$aUnited States$$xCommerce$$xLaw and legislation.
000027158 7001_ $$aArnold, R.;$$aBagley, M. A.;$$aDomeij, B.;$$aDrexl, J.;$$aDreyfuss, R. C.;$$aFackelmann, C. R.;$$aImura, T.;$$aIseki, R.;$$aLee, N.;$$aMoufang, R.;$$aUllrich, H.$$eContributors.
000027158 85641 $$uhttps://www.elgaronline.com/display/edcoll/9780857932457/9780857932457.xml$$yView eBook
000027158 942__ $$cMON$$jG 25 DRE.P$$2ddc
000027158 952__ $$w2013-09-13$$p2013-0214$$r75.00$$u41639$$bMAIN$$10$$kG 25 DRE.P$$v2013-09-13$$zTagged$$71
000027158 980__ $$aBIB$$aOS
000027158 999__ $$c29565$$d29565